

*A²
cont* 8. (Amended) An adjuvant composition as claimed in any one of claims 1 [to 7], 2 or 5, comprising a surfactant of formula (1), wherein R is C₈₋₂₀ alkyl or Phenyl C₈₋₂₀ alkyl.

A³ 13. (Amended) An adjuvant composition as claimed in any one of claims 1 [to 12], 2, 5, 9, or 11, comprising a surfactant of formula (1), wherein A is a bond, thereby forming an ether.

14. (Amended) An adjuvant composition as claimed in any one of claims 1 [to 12], 2, 5, 9, or 11, comprising a surfactant of formula (1), wherein A is -C(O)-, thereby forming an ester.

A⁴ 16. (Amended) An adjuvant composition as claimed in any one of claims 1 [to 15], 2, 5, 9, or 11, wherein the concentration of the surfactant is in the range 0.1-10%.

19. (Amended) An adjuvant combination, comprising an adjuvant as claimed in any one of claims 1 [to 17], 2, 5, 9, 11, or 18, in combination with at least one additional immunostimulant.

A⁵ 21. (Amended) An adjuvant composition as claimed in any one of claims 1 [to 20], 2, 5, 9, 11, or 18, further comprising a vehicle, said vehicle comprising of any one of the following group: chitosan or other polycationic polymers, polylactide and polylactide-co-glycolide particles, particles composed of polysaccharides or chemically modified polysaccharides, or particles composed of glycerol monoesters. *p. 8*

22. (Amended) A vaccine composition comprising an adjuvant composition as claimed in any one of claims 1 [to 21], 2, 5, 9, 11, or 18, further comprising an antigen or antigenic composition.

A⁶ 24. (Amended) A vaccine as claimed in claim 22 [or 23] wherein the vaccine is in the form of an aerosol or spray.

A⁷ 32. (Amended) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to [any of claims 22 to 24] claim 22 to the mammal.